Eli Lilly (NYSE: LLY) has been on a historic run over the past five years, outperforming similarly sized peers in the pharmaceutical industry and becoming the first healthcare stock to reach a $1 trillion market cap. The company's diabetes and weight-loss portfolio has been the main engine behind its terrific performance of late, and it remains strong. During the second quarter, Eli Lilly's revenue jumped 48% year over year to $23 billion, while adjusted earnings per share rose 33% year over year to $8.38.
Sales from Eli Lilly's Mounjaro, a diabetes medicine, soared 91% year over year to $9.9 billion, while sales of Zepbound, approved for weight loss and obstructive sleep apnea, grew 46% to $4.9 billion. Can anything stop Eli Lilly's momentum? Here's one thing that might do so.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Eli Lilly generates most of its revenue from Mounjaro and Zepbound, which have the same active ingredient, tirzepatide, a medicine that mimics the action of the GLP-1 and GIP gut hormones. In the second quarter, sales from these two medicines accounted for almost 65% of the company's top line. Eli Lilly also markets Foundayo, an oral GLP-1 approved for weight loss, although it was approved in April and doesn't yet contribute much to its financial results.
Still, the point is that Eli Lilly's lineup is concentrated at the top, with just a couple of brands responsible for most of the recent momentum. Other pharmaceutical giants are well aware of Eli Lilly's GLP-1 success, and they are seeking to launch competing therapies.
#lilly #sales #loss #billion
Sales from Eli Lilly's Mounjaro, a diabetes medicine, soared 91% year over year to $9.9 billion, while sales of Zepbound, approved for weight loss and obstructive sleep apnea, grew 46% to $4.9 billion. Can anything stop Eli Lilly's momentum? Here's one thing that might do so.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Eli Lilly generates most of its revenue from Mounjaro and Zepbound, which have the same active ingredient, tirzepatide, a medicine that mimics the action of the GLP-1 and GIP gut hormones. In the second quarter, sales from these two medicines accounted for almost 65% of the company's top line. Eli Lilly also markets Foundayo, an oral GLP-1 approved for weight loss, although it was approved in April and doesn't yet contribute much to its financial results.
Still, the point is that Eli Lilly's lineup is concentrated at the top, with just a couple of brands responsible for most of the recent momentum. Other pharmaceutical giants are well aware of Eli Lilly's GLP-1 success, and they are seeking to launch competing therapies.
#lilly #sales #loss #billion
3 hours ago
